Search Results
Your search for ASCO matches 21182 pages
Showing 6801 - 6850Adjuvant Nivolumab vs Ipilimumab in Resected Advanced Melanoma: Long-Term Follow-up of CheckMate 238
Long-term findings from the phase III CheckMate 238 study showed that nivolumab improved 4-year recurrence-free survival compared with ipilimumab in patients with resected stage IIIB to C or IV melanoma in the overall population as well as across subgroups of patients stratified by disease stage...
Does Radical Hysterectomy Improve Survival in Patients With Cervical Cancer and Intraoperative Detection of Positive Lymph Nodes?
No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom a radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of positive pelvic lymph nodes. These...
Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk
Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...
Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy
Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherapy in locally advanced (stage III) non–small cell lung cancer? The researchers enrolled patients with completely resected...
Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract...
Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with...
Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy
Thierry Andre, MD, of Hôpital Saint-Antoine, discusses phase III KEYNOTE-177 findings on the reduced risk of disease progression or death in patients receiving pembrolizumab monotherapy as a first-line treatment of microsatellite instability–high and/or mismatch repair–deficient metastatic...
Joint Statement From the AMA, AHA, and ANA on U.S. Coronavirus Death Toll
Today, the American Medical Association (AMA), American Hospital Association (AHA), and American Nurses Association (ANA) released a joint statement on the amount of deaths caused by the coronavirus in the United States. Today we mark a somber milestone as more than 200,000 people in the United...
SOLO1 5-Year Follow-up: Maintenance Olaparib for BRCA-Mutated Advanced Ovarian Cancer
Almost half of patients who received the PARP inhibitor olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data presented by Susana Banerjee, MBBS, PhD, and colleagues during the ESMO Virtual Congress 2020 (Abstract 811MO). Patients...
Can Drinking Coffee Daily Improve Survival in Patients With Advanced Colorectal Cancer?
In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and reduced risk of disease progression, according to findings reported by Mackintosh et al in JAMA Oncology. The findings, based on data from a large...
Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease
Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase III study findings from the global monarchE trial, which showed that when added to standard adjuvant endocrine therapy, abemaciclib is the first CDK4/6 inhibitor to improve invasive disease–free survival in...
Nicholas D. James, PhD, MBBS, on Prostate Cancer: Abiraterone Acetate Plus Prednisolone for Hormone-Naive Disease
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses long-term STAMPEDE trial results that showed patients with metastatic, hormone-naive prostate cancer benefited from abiraterone acetate plus prednisolone in terms of overall and failure-free survival, as well as...
Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy
Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal...
New Report Focuses on Cancer Statistics in Adolescents and Young Adults
A new report examining cancer in adolescents and young adults (AYAs, defined as diagnoses occurring between the ages of 15 and 39) provides updated estimates of the contemporary cancer burden in this age group, with predictions that 89,500 cases and 9,270 deaths will occur in this group in 2020 in...
David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the head and neck, in which the immune checkpoint inhibitor avelumab was combined with chemoradiotherapy followed by avelumab...
Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease
Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses results of the nextMONARCH study, which indicated that combining abemaciclib with tamoxifen improved overall survival. Dr. Hamilton also details adverse events in different arms of the study (Abstract 273O).
Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin
Andreas Schneeweiss, MD, of the Heidelberg University Hospital and German Cancer Research Center, discusses phase III survival data from the GeparOcto trial, which compared the neoadjuvant chemotherapy intense dose-dense EPC (epirubicin, paclitaxel, and cyclophosphamide) with weekly paclitaxel and...
World Gynecologic Oncology Awareness Day (World GO Day): September 20
Patient advocates and medical professionals in more than 20 countries have come together for the second annual World Gynecologic Oncology Day (World GO Day), taking place today, September 20. A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of...
KRAS G12C Inhibitor Shows Activity in Solid Tumors, Lung Cancer
In a phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRAS G12C inhibitor sotorasib (AMG 510) showed manageable toxicities and durable clinical benefits. Results from the trial were published in The New England Journal of Medicine, and data from the ...
Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease
Masahiro Tsuboi, MD, of Japan’s National Cancer Center Hospital East, discusses the phase III results from the ADAURA study, which showed a reduced risk of local and distant recurrence in patients with resected EGFR-mutated non–small cell lung cancer, reinforcing adjuvant osimertinib as an...
Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may ...
Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease
Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo plus letrozole, improved progression-free survival in patients with estrogen receptor–positive advanced or recurrent...
Cancer Treatment–Related Outcomes in Patients With Cancer and COVID-19
Researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19. These findings from a multicenter study presented by Trisha Wise-Draper, MD, and colleagues at the ESMO Virtual Congress 2020 (LBA71), shed light on ways standard anticancer...
Maintenance Avelumab Plus Best Supportive Care in Advanced Bladder Cancer
Findings from the JAVELIN Bladder 100 trial were published by Thomas Powles, MD, and colleagues in The New England Journal of Medicine. Researchers reported that the PD-L1 inhibitor avelumab led to a 31% reduction in risk of death, and extended median survival by more than 7 months in patients with ...
Effects of the COVID-19 Pandemic on Cancer Care, Provider Well-Being
Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to the coronavirus have generated a backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...
ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe
Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...
FDA Pipeline: Designations in Prostate Cancer, Glioblastoma, and Pediatric Leukemia
Recently, the U.S. Food and Drug Administration (FDA) granted designations to agents for metastatic castration-resistant prostate cancer, recurrent glioblastoma, and pediatric acute myeloid leukemia. Fast Track Designation for EPI-7386 in Metastatic Castration-Resistant Prostate Cancer The FDA...
Caring for Undocumented Patients With Cancer
There are approximately 25 million foreign-born immigrants living in the United States, which is more than 13% of the nation’s total population. Of these individuals, it is estimated that about 11 million are undocumented; by far, the largest group of this immigrant undocumented population is...
Viral Load May Help Predict Mortality Rate in Hospitalized Patients With Cancer and COVID-19
Higher viral loads may be associated with a greater risk of death among patients with cancer—and individuals without cancer—hospitalized with COVID-19, according to a report by Westblade et al in Cancer Cell. Among hospitalized patients infected with COVID-19, those with hematologic malignancies...
Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas
In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...
Cigarette Smoking Associated With Worse Outcomes for Patients With Bladder Cancer After Surgery
Patients treated for bladder cancer with a radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of the University of Southern California (USC). The study appeared in The Journal of Urology.1 “This study is important because...
Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer
Results from a phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti–CTLA-4) plus nivolumab (anti–PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer, an...
Role of Inherited GATA3 Variant in Response to Treatment, Disease Relapse in Pediatric ALL
Research published by Zhang et al in the Journal of the National Cancer Institute showed that an inherited variation in the GATA3 gene strongly influences early response to chemotherapy and is linked to relapse in children with acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD)...
Efficacy of High-Intensity Ultrasound Ablation for Prostate Cancer
For some patients with prostate cancer, surgery and/or radiation are considered standard treatments. However, these procedures may cause side effects, including urinary incontinence or impotency. A recent study published by Abreu et al in the Journal of Urology demonstrated that high-intensity...
Retrospective Study Explores Association Between Race/Ethnicity and Overall Survival in Colorectal Liver Metastases
A research letter published by Thornblade et al in JAMA Network Open examined the impact of race or ethnicity on rates of chemotherapy, liver resection, and survival among patients with metastatic colorectal cancer. “The unfortunate reality is that minorities, especially Black people, have a much...
National Survey Shows Decline in Overall Youth E-Cigarette Use, Uptick in Use of Disposable Products
This week, the U.S. Food and Drug Administration (FDA), in partnership with the Centers for Disease Control and Prevention, released new data from the 2020 National Youth Tobacco Survey (NYTS). The results, published by Wang et al in Morbidity and Mortality Weekly Report (MMWR), show 1.8 million...
Cryopreservation May Be Associated With Loss of Quality in Donor Stem Cell Products
During the COVID-19 pandemic, many stem cell transplant centers (including guidance from the National Marrow Donor Program [NMDP]) recommend that stem cell products be frozen for preservation. However, findings from a study by Duncan Purtill, MD, and colleagues in Blood Advances suggest that the...
ASCO Position Statement Recommends Specific Actions for Applying Telemedicine in Cancer Care During Pandemic and Beyond
A new position statement by ASCO calls for the continuation of flexibilities in reimbursement that have allowed the expanded use of telemedicine during the COVID-19 pandemic. The statement, which also calls for further research on telemedicine’s effectiveness and benefits, offers recommendations...
I Say ‘Yes’ to Life
I have been a registered nurse for almost 5 decades and was completely unprepared to hear the words “You have stage IV lung cancer.” I think receiving the diagnosis was especially shocking because the symptoms I began experiencing in the summer of 2015, including some unusual weight gain,...
New Chief of Oncologic Quality at Rutgers/Robert Wood Johnson
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, have welcomed Henry A. Pitt, MD, to its team of physicians, researchers, and administrators. Dr. Pitt is the new Chief of Oncologic Quality, a role that provides leadership and...
Roger H. Herzig, MD, Pioneer in the Treatment of Leukemia, Dies at Age 74
More than 5 decades ago, the concept of bone marrow transplantation to treat humans with leukemia was met with varying degrees of skepticism and countless clinical failures. Yet, over those same decades, bone marrow transplantation was transformed from an insurmountable therapeutic option used in a ...
Theodore Laetsch, MD, Joins Children’s Hospital of Philadelphia to Launch Very Rare Malignant Tumors Program
Pediatric hematologist-oncologist Theodore Laetsch, MD, has joined the Division of Oncology at Children’s Hospital ofPhiladelphia (CHOP), where he will launch a cutting-edge Very Rare Malignant Tumors Program that will seek to develop new treatments for children with rare and complex tumors. In...
Cervical Cancer Screening and Prevention in Low- and Middle-Income Countries: 2020
Cervical cancer is a worldwide public health problem. The incidence of the disease is particularly high in low- and middle-income countries, where low coverage of prevention strategies and high risk of infection persist. To reduce morbidity and mortality, improved screening and prevention are...
Expert Point of View: Electra D. Paskett, PhD
Formal discussant of the 2013 ASCO Plenary Abstract 2, Electra D. Paskett, PhD, Professor of Medicine at The Ohio State University, was enthusiastic about the trial results and the potential of visual inspection with acetic acid screening, as well as low-cost human papillomavirus (HPV) screening...
Simple Rapid Vinegar Screening Test Cuts Cervical Cancer Death Rates by One-Third in Rural India
In 2013, at the ASCO Annual Meeting Plenary Session, it was both surprising and encouraging in the era of personalized medicine for cancer care to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about...
Seattle Cancer Care Alliance Expands South Lake Union Campus
Seattle Cancer Care Alliance (SCCA) announced the beginning of construction on its South Lake Union campus to add a six-story, 150,000 square-foot outpatient cancer treatment clinic. The largest single construction project in SCCA history, the new building will feature a patient-centered design,...
Educate Patients at Home With ASCO Answers
Safely continue to provide trusted education materials by sending your patients to cancer.net/ascoanswers. On Cancer.Net, they will find dozens of ASCO Answers patient education materials to download for free in a PDF format. ASCO Answers materials cover a wide variety of cancer-related topics,...
Getting Up to Speed on 2021 Updates to Evaluation and Management Codes? New Resources Can Help
On January 1, 2021, significant changes to the office and outpatient Evaluation and Management (E&M) services Current Procedural Terminology (CPT®) codes (99202-99215) will go into effect. Practices, physicians, and staff must prepare in advance for these changes to ensure a successful...
Research Pioneer Marc L. Citron, MD, Establishes Grants Through Conquer Cancer
“Ask any doctor why he or she enters medicine and the answer will likely be the same,” said Marc L. Citron, MD. “People become doctors to help patients...but to deliver the moments that matter to patients—to extend their lives and give quality to their days—doctors rely on new research.” In 2003,...
